Myovant Sciences Net Income 2017-2022 | MYOV
Myovant Sciences net income from 2017 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Myovant Sciences Annual Net Income
(Millions of US $) |
| 2022 |
$-206 |
| 2021 |
$-255 |
| 2020 |
$-289 |
| 2019 |
$-274 |
| 2018 |
$-143 |
| 2017 |
$-83 |
| 2016 |
$-2 |
Myovant Sciences Quarterly Net Income
(Millions of US $) |
| 2022-12-31 |
$-58 |
| 2022-09-30 |
$-46 |
| 2022-06-30 |
$-21 |
| 2022-03-31 |
$-59 |
| 2021-12-31 |
$-63 |
| 2021-09-30 |
$-22 |
| 2021-06-30 |
$-62 |
| 2021-03-31 |
$-81 |
| 2020-12-31 |
$-74 |
| 2020-09-30 |
$-67 |
| 2020-06-30 |
$-33 |
| 2020-03-31 |
$-65 |
| 2019-12-31 |
$-86 |
| 2019-09-30 |
$-71 |
| 2019-06-30 |
$-68 |
| 2019-03-31 |
$-75 |
| 2018-12-31 |
$-71 |
| 2018-09-30 |
$-66 |
| 2018-06-30 |
$-62 |
| 2018-03-31 |
$-48 |
| 2017-12-31 |
$-42 |
| 2017-09-30 |
$-30 |
| 2017-06-30 |
$-23 |
| 2017-03-31 |
$-22 |
| 2016-12-31 |
$-8 |
| 2016-09-30 |
$-35 |
| 2016-06-30 |
$-19 |
| 2016-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.613B |
$0.231B |
|
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
|
